Jazz Pharmaceuticals PLC
JAZZ166.990USD
+0.990+0.60%
Cierre 12/19, 16:00（ET）Cotizaciones retrasadas 15 min
10.14BCap. mercado
PérdidaP/E TTM
Más Datos de Jazz Pharmaceuticals PLC Compañía
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Información de Jazz Pharmaceuticals PLC
Símbolo de cotizaciónJAZZ
Nombre de la empresaJazz Pharmaceuticals PLC
Fecha de salida a bolsaJan 18, 2012
Director ejecutivoGala (Renee D)
Número de empleados2800
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 18
DirecciónFifth Floor, Waterloo Exchange
CiudadDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postal- -
Teléfono35316347800
Sitio Webhttps://www.jazzpharma.com/
Símbolo de cotizaciónJAZZ
Fecha de salida a bolsaJan 18, 2012
Director ejecutivoGala (Renee D)
Ejecutivos de Jazz Pharmaceuticals PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.28%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
292.32K
-5.03%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.12K
-0.17%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
24.12K
-22.89%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
21.63K
-15.90%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
15.00K
--
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Director
Independent Director
13.92K
+13.93%
Ms. Anne O'Riordan
Ms. Anne O'Riordan
Independent Director
Independent Director
12.77K
+15.38%
Ms. Samantha Pearce
Ms. Samantha Pearce
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
9.24K
-5.88%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
7.11K
+31.50%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.28%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
292.32K
-5.03%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.12K
-0.17%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
24.12K
-22.89%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
21.63K
-15.90%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
15.00K
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Xywav
415.32M
39.72%
Epidiolex/epidyolex
251.73M
24.07%
Rylaze
100.66M
9.63%
Zepzelca
74.54M
7.13%
High-sodium oxybate AG royalty revenue
54.14M
5.18%
Otro
149.32M
14.28%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
936.28M
89.54%
Europe
82.76M
7.91%
All Others
26.67M
2.55%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Xywav
415.32M
39.72%
Epidiolex/epidyolex
251.73M
24.07%
Rylaze
100.66M
9.63%
Zepzelca
74.54M
7.13%
High-sodium oxybate AG royalty revenue
54.14M
5.18%
Otro
149.32M
14.28%
Estadísticas de accionistas
Actualizado: jue., 4 de dic
Actualizado: jue., 4 de dic
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.68%
BlackRock Institutional Trust Company, N.A.
8.25%
Dimensional Fund Advisors, L.P.
4.67%
Capital World Investors
4.20%
LSV Asset Management
4.13%
Otro
69.06%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.68%
BlackRock Institutional Trust Company, N.A.
8.25%
Dimensional Fund Advisors, L.P.
4.67%
Capital World Investors
4.20%
LSV Asset Management
4.13%
Otro
69.06%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
50.91%
Investment Advisor/Hedge Fund
34.93%
Hedge Fund
10.56%
Research Firm
3.49%
Individual Investor
3.02%
Pension Fund
1.77%
Venture Capital
1.30%
Bank and Trust
0.85%
Sovereign Wealth Fund
0.09%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
1197
64.03M
105.38%
-5.21M
2025Q2
1199
63.76M
105.11%
-6.47M
2025Q1
1235
63.66M
105.15%
-6.35M
2024Q4
1202
62.66M
103.17%
-6.51M
2024Q3
1172
61.48M
99.60%
-6.16M
2024Q2
1167
61.28M
97.21%
-6.97M
2024Q1
1163
63.08M
101.15%
-2.43M
2023Q4
1156
61.76M
98.11%
-3.48M
2023Q3
1158
61.08M
96.76%
-4.05M
2023Q2
1197
61.00M
95.34%
-4.11M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
6.07M
10%
+73.43K
+1.22%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.22M
8.61%
+11.23K
+0.22%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.54M
4.18%
+209.41K
+8.99%
Jun 30, 2025
Capital World Investors
2.54M
4.19%
+616.73K
+31.99%
Jun 30, 2025
LSV Asset Management
2.55M
4.21%
+87.58K
+3.55%
Jun 30, 2025
State Street Investment Management (US)
1.94M
3.19%
-31.20K
-1.59%
Jun 30, 2025
EcoR1 Capital, LLC
1.71M
2.81%
--
--
Jun 30, 2025
JP Morgan Asset Management
1.55M
2.55%
+46.92K
+3.12%
Jun 30, 2025
Fuller & Thaler Asset Management Inc.
1.63M
2.69%
+297.95K
+22.39%
Jun 30, 2025
Columbia Threadneedle Investments (US)
1.54M
2.54%
+186.67K
+13.80%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Cambria Cannabis ETF
4.08%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
3.11%
iShares U.S. Pharmaceuticals ETF
3.08%
Invesco Pharmaceuticals ETF
2.94%
State Street SPDR S&P Pharmaceuticals ETF
2.83%
Abacus FCF International Leaders ETF
2.69%
First Trust NASDAQ Pharmaceuticals ETF
2.51%
Clough Hedged Equity ETF
2.4%
Alger Russell Innovation ETF
2.12%
VictoryShares Small Cap Free Cash Flow ETF
1.77%
Ver más
Cambria Cannabis ETF
Proporción4.08%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción3.11%
iShares U.S. Pharmaceuticals ETF
Proporción3.08%
Invesco Pharmaceuticals ETF
Proporción2.94%
State Street SPDR S&P Pharmaceuticals ETF
Proporción2.83%
Abacus FCF International Leaders ETF
Proporción2.69%
First Trust NASDAQ Pharmaceuticals ETF
Proporción2.51%
Clough Hedged Equity ETF
Proporción2.4%
Alger Russell Innovation ETF
Proporción2.12%
VictoryShares Small Cap Free Cash Flow ETF
Proporción1.77%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Jazz Pharmaceuticals PLC?
Los cinco principales accionistas de Jazz Pharmaceuticals PLC son:
The Vanguard Group, Inc. posee 6.07M acciones, lo que representa el 10.00% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 5.22M acciones, lo que representa el 8.61% del total de acciones.
Dimensional Fund Advisors, L.P. posee 2.54M acciones, lo que representa el 4.18% del total de acciones.
Capital World Investors posee 2.54M acciones, lo que representa el 4.19% del total de acciones.
LSV Asset Management posee 2.55M acciones, lo que representa el 4.21% del total de acciones.
The Vanguard Group, Inc. posee 6.07M acciones, lo que representa el 10.00% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 5.22M acciones, lo que representa el 8.61% del total de acciones.
Dimensional Fund Advisors, L.P. posee 2.54M acciones, lo que representa el 4.18% del total de acciones.
Capital World Investors posee 2.54M acciones, lo que representa el 4.19% del total de acciones.
LSV Asset Management posee 2.55M acciones, lo que representa el 4.21% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Jazz Pharmaceuticals PLC?
Los tres principales tipos de accionista de Jazz Pharmaceuticals PLC son:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Dimensional Fund Advisors, L.P.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Dimensional Fund Advisors, L.P.
¿Cuántas instituciones poseen acciones de Jazz Pharmaceuticals PLC (JAZZ)?
A fecha de 2025Q3, 1197 instituciones poseen acciones de Jazz Pharmaceuticals PLC, con un valor de mercado combinado de aproximadamente 64.03M, lo que representa el 105.38% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en 0.27%.
¿Cuál es la mayor fuente de ganancias de Jazz Pharmaceuticals PLC?
El FY2025Q2, el segmento empresarial Xywav generó la ganancia más alta para Jazz Pharmaceuticals PLC, ascendiendo a 415.32M y representando el 39.72% de la ganancia total.
